Frequently asked questions in relapsed patients with myeloma
| Questions . | Considerations . |
|---|---|
| 1. To treat or not to treat asymptomatic relapses | When treatment can be safely delayed? |
| When early treatment should be administered? | |
| 2. When retreatment should be considered | What should be the response duration cutoff? |
| 3. Which are the best drug associations? | Additive effect? |
| Synergistic effect? | |
| 4. How to use available drugs | Sequential approach? |
| Multidrug combination approach? | |
| 5. For how long should a rescue treatment be continued | Limited number of cycles? |
| Indefinite? | |
| 6. When to consider a rescue second ASCT? | What should be the minimal response duration from the first ASCT? |
| 7. Is there a role for allogeneic transplantation? | When should it be considered? |
| Questions . | Considerations . |
|---|---|
| 1. To treat or not to treat asymptomatic relapses | When treatment can be safely delayed? |
| When early treatment should be administered? | |
| 2. When retreatment should be considered | What should be the response duration cutoff? |
| 3. Which are the best drug associations? | Additive effect? |
| Synergistic effect? | |
| 4. How to use available drugs | Sequential approach? |
| Multidrug combination approach? | |
| 5. For how long should a rescue treatment be continued | Limited number of cycles? |
| Indefinite? | |
| 6. When to consider a rescue second ASCT? | What should be the minimal response duration from the first ASCT? |
| 7. Is there a role for allogeneic transplantation? | When should it be considered? |